NCT07188558Phase 3Recruiting

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Study sponsor: Lyell Immunopharma, Inc. · LYEL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-12Estimated

Enrollment · participants400Estimated

Source updated2026-08-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-12-09 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Large B-cell Lymphoma; Lymphoma, B-Cell; Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma Refractory/ Relapsed; Diffuse Large B Cell Lymphoma (DLBCL); Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B Cell Lymphoma Relapsed

Treatments or interventions studied

rondecabtagene autoleucelBiologicalAlso known as LYL314
axicabtagene ciloleucelBiologicalAlso known as Yescarta, axi-cel
lisocabtagene maraleucelBiologicalAlso known as Breyanzi, liso-cel

Primary outcomes · main study measures

measure: Event free survival; description: The time interval from treatment initiation until the occurrence of a specific event of interest.; timeFrame: 36 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history